MedSafety Solutions Earns EU-MDR Certification

Meets New, Strengthened Requirements for Safety and Performance

MedSafety Solutions today announced that it has received the European Union Medical Devices Regulations (EU-MDR) certification as of September 9, 2021.

This achievement is a major milestone for MedSafety Solutions in its ongoing mission to provide hospital pharmacies in the European market with the products and expertise they need to perform safely and effectively.

The British Standards Institution BSI completed their conformity assessment to include quality management systems as well as general safety and performance standards. As a result of this assessment, conducted by audit and technical review, BSI determined that MedSafety Solutions met the needed requirements and issued its EU Quality Management System Certificate.

“Receiving this certification demonstrates our commitment to compliance with new regulations and to meeting customers’ needs safely and predictably,” says Steve van Engen, founder and CEO at MedSafety Solutions. “Additionally, receiving this certification ahead of many other companies will serve as a distinct competitive advantage.”

This news takes on significant importance in that the new certification:

  • Is significantly more stringent than the Medical Devices Directive (MDD), the previous regulatory framework
  • Comes as a result of strict performance assessments of MedSafety Solution’s quality management systems and an evaluation of general safety and performance indicators
  • Enables MedSafety Solutions to advance its position in the European market

To learn more about the EU-MDR certification, click here to contact us.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy